Using MPC's to help treat T1D is STILL very much on the cards - attempts in the past were not meant to be curative in nature - only to slow the conditions onset, with no clinical data to support success. MPC's have however, been shown to work very well at [conceptually] restoring beta cell function in T1D's - when used in conjunction with other drugs now under development, see linked item for more information http://medicine.missouri.edu/news/0192.php
MSB is of course focused on T2D and complications of D, where we can [likely] make a very real difference. Obviously, no-one can make "slam dunk" statements yet, regarding treatment facts, as we simply don't have the data with trials ongoing, but our initial data for T2D was encouraging.
fresh v frozen, page-18
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |